The European Society for Medical Oncology (ESMO) 2026 congress will take place in Madrid, Spain, from October 23 to 27. Standing alongside ASCO and WCLC as a global top oncology academic event, ESMO showcases the year's most clinically valuable advances through its highly selective program. This year, 12 studies across three innovative medicines from Simcere Zaiming—Envafolimab (Enweida®), Cetuximab β (Enlituo®), and Trilaciclib (COSELA®)—have been accepted, covering lung cancer, biliary tract cancer, colorectal cancer, cervical cancer, soft tissue sarcoma and more. From precision targeted therapy and immunotherapy to myeloprotection, the data underscore the strength of China's clinical R&D.
Envafolimab (Enweida®)
Six Studies Expand the Boundaries of Subcutaneous Immunotherapy
1) Registrational Phase III in Biliary Tract Cancer
Subcutaneous anti-PD-L1 monoclonal antibody Envafolimab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment for advanced biliary tract cancer in Chinese patients: A randomized, open-label, multicenter, registrational phase III trial
Presentation: Rapid Oral
Abstract #: 473RO
Investigator: Shukui Qin (Nanjing Tianyinshan Hospital)
2) Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Envafolimab Plus Nab-Paclitaxel and Platinum as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC): An Open-Label, Single-Arm, Phase II Trial
Presentation: Poster
Abstract #: 3828P
Investigator: Jian Zhang (Zhujiang Hospital, Southern Medical University)
3) Soft Tissue Sarcoma
Phase II Study of First-line Envafolimab in Combination with Liposomal Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma
Presentation: Poster
Abstract #: 3746P
Investigator: Ying Dong (The Second Affiliated Hospital, Zhejiang University School of Medicine)
4) Neoadjuvant Therapy in Locally Advanced Colon Cancer
Envafolimab (anti-PD-L1) as Monotherapy or in Combination with CAPEOX for Neoadjuvant Treatment of Locally Advanced Colon Cancer: A Prospective, Single-Center, Dual-Cohort Clinical Trial (NCT06014372)
Presentation: Poster
Abstract #: 839P
Investigator: Zhenhai Lu (Sun Yat-sen University Cancer Center)
5) KRAS G12C-Mutated mCRC
Efficacy and safety of IBI351 plus cetuximabβ ± FOLFIRI in patients with KRAS G12C-mutated metastatic colorectal cancer (the CRUCIAL study)
Presentation: e-Poster
Abstract #: 885eP
Investigator: Ying Yuan (The Second Affiliated Hospital, Zhejiang University School of Medicine)
6) Elderly Patients with Gallbladder Cancer
First-Line Envafolimab, Lenvatinib, and Capecitabine for Elderly Patients With Unresectable or Metastatic Gallbladder Cancer: A Single-Arm Exploratory Study
Presentation: e-Poster
Abstract #: 499eP
Investigator: Fan Huang (The First Affiliated Hospital of Anhui Medical University)
Cetuximabβ (Enlituo®)
Three Studies Advancing Colorectal Cancer Care
1) High-Risk pMMR/MSS Locally Advanced Rectal Cancer
SCRT combined with mFOLFOX6, sintilimab, and genotype-guided targeted therapy in high-risk pMMR/MSS rectal cancer: primary analysis of the multicenter phase II CRIT study
Presentation: Poster
Abstract #: 3539P
Investigator: Jun Huang (The Sixth Affiliated Hospital, Sun Yat-sen University)
2) CRIT-II: Randomized Phase III Trial Design
CRIT-II: a randomized phase III trial of SCRT followed by mFOLFOX6 with sintilimab and genotype-guided targeted therapy in high-risk pMMR/MSS rectal cancer
Presentation: e-Poster
Abstract #: 3583eTiP
Investigator: Jun Huang (The Sixth Affiliated Hospital, Sun Yat-sen University)
3) First-Line pMMR RAS/BRAF Wild-Type mCRC
CONCEPT (COmbinatioN of CEtuximab Plus fruquintinib Treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer
Presentation: e-Poster
Abstract #: 890eP
Investigator: Kefeng Ding (The Second Affiliated Hospital, Zhejiang University School of Medicine)
Trilaciclib (COSELA®)
Three Studies Reinforcing the Value of Myeloprotection
1) Myeloprotection in Cervical Cancer During Chemoradiotherapy
Trilaciclib for the prevention of chemotherapy-induced myelosuppression during induction chemotherapy followed by chemoradiotherapy in locally advanced cervical cancer: A prospective, single-arm, phase II study
Presentation: Poster
Abstract #: 3930P
Investigator: Lina Zhao (Xijing Hospital)
2) Limited-Stage SCLC: Chemotherapy Followed by Sequential Radiotherapy
Trilaciclib for myeloprotection in limited-stage small cell lung cancer receiving first-line chemotherapy with sequential thoracic radiotherapy: an exploratory non-randomized controlled study
Presentation: Poster
Abstract #: 3832P
Investigator: Jinghui Bai (Liaoning Cancer Hospital)
3) Real-World Study Across Solid Tumor Types with Immunotherapy/Radiotherapy
Myeloprotective efficacy of trilaciclib combined with chemotherapy across solid tumor types: a real-world retrospective study
Presentation: e-Poster
Abstract #: 4054eP
Investigator: Yuyu Zhang (The First Hospital of Jilin University)